HC Wainwright & Co. Initiates Coverage On Vanda Pharma with Buy Rating, Announces Price Target of $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Vanda Pharmaceuticals with a Buy rating and set a price target of $18.
October 31, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Vanda Pharmaceuticals with a Buy rating and a price target of $18, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $18 by HC Wainwright & Co. suggests a positive outlook for Vanda Pharmaceuticals. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100